- 2025.05.12(Scheduled for May 21) General Manager of our Shin-Kawasaki Research Institute to Present Research Results at 11th Novalix Conference
- 2025.05.09Non-consolidated Financial Results for the Three Months Ended March 31,2025 [Under Japanese GAAP]
- 2025.05.09Financial Results - Fiscal Year Ended December 31,2025, 1st Quarter
- 2025.04.08Veritas In Silico to Announce Financial Results for the First Quarter of FY2025 on May 9
- 2025.03.12(Scheduled for Apr. 15) Invited Lecture: Using AI for mRNA-Targeted Small Molecule Drug Discovery – Our CSO to Present at the 20th Annual Drug Discovery Chemistry Conference
- 2025.02.20Reduction of Capital Stock (Capital Reduction)
- 2025.02.20Appointing Candidates for Director and Alternate Audit & Supervisory Board Member
- 2025.02.20Organizational Reforms and Personnel Changes
- 2025.02.18(Scheduled for Mar. 28) Representative Nakamura to Present at the 105th CSJ Annual Meeting
- 2025.02.13Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2024 [Under Japanese GAAP]
- 2024.06.19Veritas In Silico Announces Milestone Achievement in Collaborative Research with Takeda
- 2024.02.08Veritas In Silico Listed on the Growth Market of the Tokyo Stock Exchange
- 2023.12.21RaQualia Pharma and Veritas In Silico announce that both companies have achieved the milestone in a joint research collaboration for mRNA-targeted small molecule drug discovery
- 2023.12.08Mitsubishi Gas Chemical and Veritas In Silico start to discuss the research collaboration of RNA targeting drug discovery program
- 2023.06.23Veritas In Silico and Takeda Enter Into Collaborative Research and License Agreement for mRNA-Targeted Small Molecule Drugs
- 2023.05.22Oncodesign Services and Veritas In Silico enter into business cooperation on developing mRNA-targeted small molecule drugs
- 2022.12.27RaQualia Pharma and Veritas in Silico enter into a new joint research agreement for mRNA-targeted small molecule drug discovery
- 2022.10.04Veritas In Silico Begins RNase-Recruiting Small Molecule Screening for RIBOTAC Design and Synthesis
- 2021.12.27Veritas In Silico Announces 1.4 Billion JPY (Approx. $12.2 Million) Series C Financing
- 2021.11.25Veritas in Silico Signs Joint Drug Discovery Research Agreement with Shionogi
- 2025.05.12(Scheduled for May 21) General Manager of our Shin-Kawasaki Research Institute to Present Research Results at 11th Novalix Conference
- 2025.04.08Veritas In Silico to Announce Financial Results for the First Quarter of FY2025 on May 9
- 2025.03.12(Scheduled for Apr. 15) Invited Lecture: Using AI for mRNA-Targeted Small Molecule Drug Discovery – Our CSO to Present at the 20th Annual Drug Discovery Chemistry Conference
- 2025.02.18(Scheduled for Mar. 28) Representative Nakamura to Present at the 105th CSJ Annual Meeting
- 2025.01.14Veritas In Silico to Announce FY2024 Financial Results on February 13
- 2025.01.08(Report) Representative Nakamura Delivers a Lecture at the Chemistry Committee Joint Meeting of the Science Council of Japan
- 2024.11.29(Report) Veritas In Silico participate in the 41st Medicinal Chemistry Symposium
- 2024.11.12(Report) CSO’s talk in the Company Presentations session at BIO-Europe 2024
- 2024.10.24Veritas In Silico Inc. to Announce Third Quarter Fiscal Year 2024 Financial Results on November 13
- 2024.10.18(Scheduled for Nov. 4) CSO to present in the Company Presentations session at BIO Europe 2024
- 2025.05.09Non-consolidated Financial Results for the Three Months Ended March 31,2025 [Under Japanese GAAP]
- 2025.05.09Financial Results - Fiscal Year Ended December 31,2025, 1st Quarter
- 2025.02.20Reduction of Capital Stock (Capital Reduction)
- 2025.02.20Appointing Candidates for Director and Alternate Audit & Supervisory Board Member
- 2025.02.20Organizational Reforms and Personnel Changes
- 2025.02.13Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2024 [Under Japanese GAAP]
- 2025.02.13Financial Results - Fiscal Year Ended December 31, 2024
- 2025.02.13Company Presentation
- 2024.12.30Patent owned by Veritas In Silico to Become Effective in Europe
- 2024.12.23Liverpool ChiroChem and VIS to Enter into a Collaboration Development & Commercialization Agreement for mRNA-targeted Small Molecule Drugs
